ADAM8 as a drug target in pancreatic cancer

ADAM8 as a drug target in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) has a grim prognosis with <5% survivors after 5 years. High expression levels of ADAM8, a metalloprotease disintegrin, are correlated with poor clinical outcome. We show that ADAM8 expression is associated with increased migration and invasiveness of PDAC c...

Full description

Bibliographic Details
Main Authors: Schlomann, Uwe (Author), Koller, Garrit (Author), Conrad, Catharina (Author), Ferdous, Taheera (Author), Golfi, Panagiota (Author), Garcia, Adolfo Molejon (Author), Höfling, Sabrina (Author), Parsons, Maddy (Author), Costa, Patricia (Author), Soper, Robin (Author), Bossard, Maud (Author), Hagemann, Thorsten (Author), Roshani, Rozita (Author), Sewald, Norbert (Author), Ketchem, Randal R. (Author), Moss, Marcia L. (Author), Rasmussen, Fred H. (Author), Tuveson, David A. (Author), Nimsky, Christopher (Author), Bartsch, Jörg W. (Author), Miller, Miles Aaron (Contributor), Lauffenburger, Douglas A (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering (Contributor)
Format: Article
Language:English
Published: Nature Publishing Group, 2017-02-15T16:14:44Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items